cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Oncternal Therapeutics Inc
8 own
23 watching
Current Price
$8.51
$0.09
(1.02%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
35.26M
52-Week High
52-Week High
20.80000
52-Week Low
52-Week Low
5.20000
Average Volume
Average Volume
0.01M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization35.26M
icon52-Week High20.80000
icon52-Week Low5.20000
iconAverage Volume0.01M
iconDividend Yield--
iconP/E Ratio--
What does the Oncternal Therapeutics Inc do?
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company s clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
Read More
How much money does Oncternal Therapeutics Inc make?
News & Events about Oncternal Therapeutics Inc.
Ticker Report
10 months ago
Maxim Group downgraded shares of Oncternal Therapeutics (NASDAQ:ONCT Get Rating) from a buy rating to a hold rating in a research report released on Tuesday, The Fly reports. Other equities research analysts have also recently issued reports about the stock. HC Wainwright cut shares of ...
Globe Newswire
11 months ago
SAN DIEGO, March 27, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Erik S. Nelson, who joined Oncternal ...
Zolmax
11 months ago
Oncternal Therapeutics (NASDAQ:ONCT Get Rating) had its price target reduced by equities researchers at Oppenheimer from $14.00 to $9.00 in a research note issued on Wednesday, Benzinga reports. The firm presently has an outperform rating on the stock. Several other research ...
Benzinga
11 months ago
read more...
Globe Newswire
1 year ago
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that interim clinical data from the ongoing Phase 1/2 Study CIRM-0001 will be presented in an ...
Frequently Asked Questions
Frequently Asked Questions
What is Oncternal Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Oncternal Therapeutics Inc shares?
plus_minus_icon
How can I buy Oncternal Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Oncternal Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Oncternal Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Oncternal Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Oncternal Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Oncternal Therapeutics Inc?
plus_minus_icon
What percentage is Oncternal Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Oncternal Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$8.51
$0.09
(1.02%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00